Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy
暂无分享,去创建一个
Philippe Hantraye | Tomas Björklund | Marie-Claude Grégoire | Laurent Besret | Frédéric Dollé | Nicole Déglon | M. Grégoire | N. Déglon | R. Mandel | Tomas Björklund | D. Kirik | F. Dollé | P. Hantraye | L. Leriche | T. Carlsson | L. Besret | Thomas Carlsson | Deniz Kirik | N. Breysse | Ronald J. Mandel | Ludovic Leriche | Nathalie Breysse | T. Björklund
[1] L. Schiffer,et al. Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.
[2] J. D. Parkes,et al. "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY , 1976, The Lancet.
[3] O. Hornykiewicz,et al. Receptor basis for dopaminergic supersensitivity in Parkinson's disease , 1978, Nature.
[4] C. Marsden,et al. Control of on/off phenomenon by continuous intravenous infusion of levodopa , 1984, Neurology.
[5] L. Swanson. The Rat Brain in Stereotaxic Coordinates, George Paxinos, Charles Watson (Eds.). Academic Press, San Diego, CA (1982), vii + 153, $35.00, ISBN: 0 125 47620 5 , 1984 .
[6] T Greitz,et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[7] I. Shoulson,et al. Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations , 1986, Annals of neurology.
[8] J. Obeso,et al. LISURIDE INFUSION PUMP: A DEVICE FOR THE TREATMENT OF MOTOR FLUCTUATIONS IN PARKINSON'S DISEASE , 1986, The Lancet.
[9] M. Savasta,et al. Denervation supersensitivity of striatal D2 dopamine receptors is restricted to the ventro- and dorsolateral regions of the striatum , 1987, Neuroscience Letters.
[10] T. Chase,et al. Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies , 1987, Annals of neurology.
[11] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[12] J. Bartko,et al. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II , 1988, Annals of neurology.
[13] A. Crossman,et al. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat , 1990, Brain Research.
[14] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[15] D. Abrous,et al. Intrastriatal Dopamine‐rich Implants Reverse the Increase of Dopamine D2 Receptor mRNA Levels Caused by Lesion of the Nigrostriatal Pathway: A Quantitative In Situ Hybridization Study , 1992, The European journal of neuroscience.
[16] R. Sunahara,et al. The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. , 1992, European journal of pharmacology.
[17] Bernard Bendriem,et al. Modeling Analysis of [11C]Flumazenil Kinetics Studied by PET: Application to a Critical Study of the Equilibrium Approaches , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[18] C Crouzel,et al. Quantification of Benzodiazepine Receptors in Human Brain Using PET, [11C]Flumazenil, and a Single-Experiment Protocol , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[19] N. Alpert,et al. In vivo imaging of neuromodulatory synaptic transmission using PET: A review of relevant neurophysiology , 1995 .
[20] S. Nishiyama,et al. Effects of Binge Pattern Cocaine Administration on Dopamine D1 and D2 Receptors in the Rat Brain: AnIn Vivo Study Using Positron Emission Tomography , 1996, The Journal of Neuroscience.
[21] R P Maguire,et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. , 1997, Brain : a journal of neurology.
[22] Christer Halldin,et al. Effect of reserpine‐induced depletion of synaptic dopamine on [11C]Raclopride binding to D2‐dopamine receptors in the monkey brain , 1997, Synapse.
[23] S. Leff,et al. Characterization of Intrastriatal Recombinant Adeno-Associated Virus-Mediated Gene Transfer of Human Tyrosine Hydroxylase and Human GTP-Cyclohydrolase I in a Rat Model of Parkinson’s Disease , 1998, The Journal of Neuroscience.
[24] J. Schneider,et al. Differential regulation of striatal dopamine D1 and D2 receptors in acute and chronic parkinsonian monkeys , 1999, Brain Research.
[25] Christer Halldin,et al. Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand (11C)raclopride from (11C)methyl triflate , 1999 .
[26] C. Warren Olanow,et al. Levodopa motor complications in Parkinson's disease , 2000, Trends in Neurosciences.
[27] J. Nutt,et al. Continuous dopamine-receptor stimulation in advanced Parkinson's disease , 2000, Trends in Neurosciences.
[28] A. Björklund,et al. Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System , 2000, The Journal of Neuroscience.
[29] T. Schallert,et al. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury , 2000, Neuropharmacology.
[30] B. Byrne,et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. , 2001, Human gene therapy.
[31] J. Holden,et al. Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP‐treated monkeys: PET studies with [11C]raclopride , 2002, Synapse.
[32] A. Björklund,et al. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l-dopa using rAAV-mediated gene transfer , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[33] J Tauscher,et al. Dopamine depletion results in increased neostriatal D2 receptor binding in humans , 2002, Molecular Psychiatry.
[34] J Tauscher,et al. Dopamine depletion results in increased neostriatal D2, but not D1, receptor binding in humans , 2002, Molecular Psychiatry.
[35] S. Kapur,et al. In vivo evidence for dopamine-mediated internalization of D2-receptors after amphetamine: differential findings with [3H]raclopride versus [3H]spiperone. , 2003, Molecular pharmacology.
[36] M. Kay,et al. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[37] Lee W. Schruben,et al. Modeling & Analysis , 2003, NeuroImage.
[38] Nicola Pavese,et al. Endogenous dopamine release after pharmacological challenges in Parkinson's disease , 2003, Annals of neurology.
[39] Vesna Sossi,et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. , 2004, Brain : a journal of neurology.
[40] Z. Xu,et al. Asymmetrical changes of dopamine receptors in the striatum after unilateral dopamine depletion , 2005, Brain Research.
[41] A. Björklund,et al. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. , 2005, Brain : a journal of neurology.
[42] Philip Seeman,et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] Multiinjection Approach for D2 Receptor Binding Quantification in Living Rats using [11C]Raclopride and the β-Microprobe: Crossvalidation with in Vitro Binding Data , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[44] U. Siebert,et al. Cost of Parkinson's disease in Europe , 2005, European journal of neurology.
[45] Christer Halldin,et al. Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: A comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride , 2006, Synapse.
[46] Fabrizio Stocchi,et al. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications , 2006, The Lancet Neurology.
[47] David Eidelberg,et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.
[48] V. Calabrese,et al. PROJECTED NUMBER OF PEOPLE WITH PARKINSON DISEASE IN THE MOST POPULOUS NATIONS, 2005 THROUGH 2030 , 2007, Neurology.
[49] Tomas Björklund,et al. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. , 2007, Current gene therapy.
[50] A. Stoessl. Gene therapy for Parkinson's disease: early data , 2007, The Lancet.
[51] C. Tanner,et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.
[52] R. Bakay,et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial , 2008, The Lancet Neurology.
[53] J. L. Eberling,et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease , 2008, Neurology.
[54] E. London,et al. Estimation of D2-like Receptor Occupancy by Dopamine in the Putamen of Hemiparkinsonian Monkeys , 2008, Neuropsychopharmacology.